Pharmya

  • Home
  • About us
  • Services
    • Pharmacovigilance Systems
    • Operational Pharmacovigilance Activities
    • EU QPPV & Local QPPV services
    • Pharmacovigilance Audits and Training
  • News
  • Careers
  • Contact us
  • English
  • Français
  • Español
You are here: Pharmya > All news > Covid-19 Vaccine Surveillance Update – Period 17-Jun-2022 to 21-Jul-2022

https://ansm.sante.fr/actualites/point-de-situation-sur-la-surveillance-des-vaccins-contre-le-covid-19-periode-du-17-06-2022-au-21-07-2022

Marie Berger 5 August 2022 All news
  • ← The risk of myocarditis is increased but remains low after the first booster dose with an mRNA vaccine, and this risk decreases with increasing time between doses
  • Product Management Service (PMS) – Implementation of International Organization for Standardization (ISO) standards for the identification of medicinal products (IDMP) in Europe →

Pharmya – Pharmacovigilance

PHARMYA is a French based company, dedicated to providing Pharmacovigilance services. Its mission is to support the pharmaceutical industry, biotechnology companies, research centers and their service providers in their efforts to comply with international Pharmacovigilance regulations.

Contact

  • PHARMYA
  • 315 Av. Saint Sauveur du Pin
  • 34980 Saint Clément de Rivière (Montpellier), France
  • Phone: +33 411 93 21 10
  • Email: info@pharmya.com
  • Website: www.pharmya.com

News

  • FAQ for the webinar on the new European legislation on clinical trials for medicinal products
  • EMA: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 10 – 12 May 2023
  • EMA – Annual Report 2022
Copyright © 2018 - Pharmya - Legal terms - Quality Policy